These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1236 related items for PubMed ID: 24486412

  • 21. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
    Han P, Li H, Jiang X, Zhai B, Tan G, Zhao D, Qiao H, Liu B, Jiang H, Sun X.
    Mol Oncol; 2017 Mar; 11(3):320-334. PubMed ID: 28164434
    [Abstract] [Full Text] [Related]

  • 22. Exosomes derived from HCC cells induce sorafenib resistance in hepatocellular carcinoma both in vivo and in vitro.
    Qu Z, Wu J, Wu J, Luo D, Jiang C, Ding Y.
    J Exp Clin Cancer Res; 2016 Sep 30; 35(1):159. PubMed ID: 27716356
    [Abstract] [Full Text] [Related]

  • 23. Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines.
    Pino MS, Shrader M, Baker CH, Cognetti F, Xiong HQ, Abbruzzese JL, McConkey DJ.
    Cancer Res; 2006 Apr 01; 66(7):3802-12. PubMed ID: 16585207
    [Abstract] [Full Text] [Related]

  • 24. MK2206 overcomes the resistance of human liver cancer stem cells to sorafenib by inhibition of pAkt and upregulation of pERK.
    Zhai B, Zhang X, Sun B, Cao L, Zhao L, Li J, Ge N, Chen L, Qian H, Yin Z.
    Tumour Biol; 2016 Jun 01; 37(6):8047-55. PubMed ID: 26711788
    [Abstract] [Full Text] [Related]

  • 25. Opposite functions of HIF-α isoforms in VEGF induction by TGF-β1 under non-hypoxic conditions.
    Chae KS, Kang MJ, Lee JH, Ryu BK, Lee MG, Her NG, Ha TK, Han J, Kim YK, Chi SG.
    Oncogene; 2011 Mar 10; 30(10):1213-28. PubMed ID: 21057546
    [Abstract] [Full Text] [Related]

  • 26. Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells.
    Dong J, Zhai B, Sun W, Hu F, Cheng H, Xu J.
    PLoS One; 2017 Mar 10; 12(9):e0185088. PubMed ID: 28934275
    [Abstract] [Full Text] [Related]

  • 27. Sorafenib blocks the activation of the HIF-2α/VEGFA/EphA2 pathway, and inhibits the rapid growth of residual liver cancer following high-intensity focused ultrasound therapy in vivo.
    Wu L, Zhou J, Zhou W, Huang XF, Chen Q, Wang W, Zhai L, Li S, Tang Z.
    Pathol Res Pract; 2021 Apr 10; 220():153270. PubMed ID: 33640712
    [Abstract] [Full Text] [Related]

  • 28. Sorafenib reduces hepatic infiltrated regulatory T cells in hepatocellular carcinoma patients by suppressing TGF-beta signal.
    Wang Q, Yu T, Yuan Y, Zhuang H, Wang Z, Liu X, Feng M.
    J Surg Oncol; 2013 Mar 10; 107(4):422-7. PubMed ID: 22833259
    [Abstract] [Full Text] [Related]

  • 29. Growth arrest DNA damage-inducible gene 45 gamma expression as a prognostic and predictive biomarker in hepatocellular carcinoma.
    Ou DL, Shyue SK, Lin LI, Feng ZR, Liou JY, Fan HH, Lee BS, Hsu C, Cheng AL.
    Oncotarget; 2015 Sep 29; 6(29):27953-65. PubMed ID: 26172295
    [Abstract] [Full Text] [Related]

  • 30. Sorafenib enhances proteasome inhibitor-mediated cytotoxicity via inhibition of unfolded protein response and keratin phosphorylation.
    Honma Y, Harada M.
    Exp Cell Res; 2013 Aug 15; 319(14):2166-78. PubMed ID: 23727131
    [Abstract] [Full Text] [Related]

  • 31. Radiosensitivity enhancement of human hepatocellular carcinoma cell line SMMC-7721 by sorafenib through the MEK/ERK signal pathway.
    Dai XF, Ding J, Zhang RG, Ren JH, Ma CM, Wu G.
    Int J Radiat Biol; 2013 Sep 15; 89(9):724-31. PubMed ID: 23682582
    [Abstract] [Full Text] [Related]

  • 32. COX-2/PGE2 Axis Regulates HIF2α Activity to Promote Hepatocellular Carcinoma Hypoxic Response and Reduce the Sensitivity of Sorafenib Treatment.
    Dong XF, Liu TQ, Zhi XT, Zou J, Zhong JT, Li T, Mo XL, Zhou W, Guo WW, Liu X, Chen YY, Li MY, Zhong XG, Han YM, Wang ZH, Dong ZR.
    Clin Cancer Res; 2018 Jul 01; 24(13):3204-3216. PubMed ID: 29514844
    [Abstract] [Full Text] [Related]

  • 33. In vitro study of normoxic epidermal growth factor receptor-induced hypoxia-inducible factor-1-alpha, vascular endothelial growth factor, and BNIP3 expression in head and neck squamous cell carcinoma cell lines: Implications for anti-epidermal growth factor receptor therapy.
    Secades P, de Santa-María IS, Merlo A, Suarez C, Chiara MD.
    Head Neck; 2015 Aug 01; 37(8):1150-62. PubMed ID: 24798801
    [Abstract] [Full Text] [Related]

  • 34. Metformin inhibits the invasion of human hepatocellular carcinoma cells and enhances the chemosensitivity to sorafenib through a downregulation of the ERK/JNK-mediated NF-κB-dependent pathway that reduces uPA and MMP-9 expression.
    Hsieh SC, Tsai JP, Yang SF, Tang MJ, Hsieh YH.
    Amino Acids; 2014 Dec 01; 46(12):2809-22. PubMed ID: 25245054
    [Abstract] [Full Text] [Related]

  • 35. Mild chronic hypoxia-induced HIF-2α interacts with c-MYC through competition with HIF-1α to induce hepatocellular carcinoma cell proliferation.
    Mu H, Yu G, Li H, Wang M, Cui Y, Zhang T, Song T, Liu C.
    Cell Oncol (Dordr); 2021 Oct 01; 44(5):1151-1166. PubMed ID: 34339013
    [Abstract] [Full Text] [Related]

  • 36. Validation of VX2 as a Hepatocellular Carcinoma Model: Comparison of the Molecular Reaction of VX2 and HepG2 Tumor Cells to Sorafenib In Vitro.
    Nass N, Streit S, Wybranski C, Jürgens J, Brauner J, Schulz N, Powerski M, Ricke J, Kalinski T, Dudeck O, Seidensticker M.
    Anticancer Res; 2017 Jan 01; 37(1):87-93. PubMed ID: 28011478
    [Abstract] [Full Text] [Related]

  • 37. Sodium orthovanadate overcomes sorafenib resistance of hepatocellular carcinoma cells by inhibiting Na+/K+-ATPase activity and hypoxia-inducible pathways.
    Jiang W, Li G, Li W, Wang P, Xiu P, Jiang X, Liu B, Sun X, Jiang H.
    Sci Rep; 2018 Jun 26; 8(1):9706. PubMed ID: 29946188
    [Abstract] [Full Text] [Related]

  • 38. 2-Methoxyestradiol synergizes with Erlotinib to suppress hepatocellular carcinoma by disrupting the PLAGL2-EGFR-HIF-1/2α signaling loop.
    Zheng S, Ni J, Li Y, Lu M, Yao Y, Guo H, Jiao M, Jin T, Zhang H, Yuan A, Wang Z, Yang Y, Chen Z, Wu H, Hu W.
    Pharmacol Res; 2021 Jul 26; 169():105685. PubMed ID: 34022398
    [Abstract] [Full Text] [Related]

  • 39. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
    Cui SX, Shi WN, Song ZY, Wang SQ, Yu XF, Gao ZH, Qu XJ.
    Oncotarget; 2016 Jun 14; 7(24):36767-36782. PubMed ID: 27167344
    [Abstract] [Full Text] [Related]

  • 40. Ascochlorin inhibits growth factor-induced HIF-1α activation and tumor-angiogenesis through the suppression of EGFR/ERK/p70S6K signaling pathway in human cervical carcinoma cells.
    Jeong JH, Jeong YJ, Cho HJ, Shin JM, Kang JH, Park KK, Park YY, Chung IK, Chang HW, Magae J.
    J Cell Biochem; 2012 Apr 14; 113(4):1302-13. PubMed ID: 22109717
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 62.